- Background: Rituximab is a promising steroid sparing agent used in the treatment of moderate to severe pemphigus vulgaris. Its exact place in the algorithm of pemphigus treatment, vis-a-vis other, conventional adjuvant therapy (CAT) is not known.
Objective: To describe and compare disease course outcomes and morbidity among patients with moderate to severe pemphigus who received rituximab therapy (RT) in addition to prednisone and CAT, versus those who were treated with prednisone and CAT alone.
Methods: A 16-year retrospective case control study was designed with adult patients who were seen at the Duke University Dermatology Immunodermatology clinic from 1999-2015, who had a diagnosis of pemphigus vulgaris, and required prednisone and at least 1 systemic CAT. All patients had at least 6 months follow up from the initial visit. Interventions included RT, systemic CAT, and prednisone. The main outcome measured was prednisone intake. Secondary outcomes were complete remission (CR) and partial remission (PR).
Results: 40 patients were included in the study. All initially received prednisone and at least 1 systemic CAT. 13/40 eventually went on to receive RT, while 27/40 remained on CAT (CAT-only). Patients in the RT group, pre-RT, had a median prednisone intake of 658.57 mg/month. Rituximab treatment significantly reduced this to 177.22 mg/month (p=0.002). Median prednisone intake of the CAT-only group was 141.33 mg/month. This was significantly less than Pre-RT (p=0.01) and on par with Post-RT intake (p=0.58). 54% of patients in the RT group and 64% of those in the CAT-only group achieved CR. All patients in the RT group and 96% of those in the CAT-only group achieved at least PR.
Conclusions: 32.5% of our patients with moderate to severe pemphigus vulgaris failed prednisone and traditional CAT treatment and required rituximab therapy. Rituximab reduced the monthly prednisone intake in these patients by 73%. This suggests that there is a subset of patients with moderate to severe pemphigus who may benefit from early institution of rituximab therapy. Rituximab significantly reduces the monthly prednisone requirement among CAT-resistant pemphigus vulgaris patients to levels on par with CAT-responsive patients. ... [Read More]
- Total Size
- 4 files (44.3 KB)
- Data Citation
- Agarwal, A.; Bañez, L. L.; Hall, R. P.; Cardones, A. R. (2018). Data from: Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. Duke Digital Repository. https://dx.doi.org/10.7924/r4vh5gw86
- Publication Date
- June 5, 2018
- Collection Dates
- 1999 to 2015
- Related Materials
- Adela R. Cardones: firstname.lastname@example.org
- Data from: Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis